Trials / Completed
CompletedNCT04516993
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II
Prospective, Multicenter, Open, End-point Blinded, Stratified Block Randomized, Parallel Positive Controlled Clinical Trial of Tenecteplase in Acute Ischemic Stroke With Large Vessel Occlusion Over Time Window
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- Huashan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy and safety of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenecteplase | Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg) |
| DRUG | The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy) | Best treatment arm |
Timeline
- Start date
- 2021-09-28
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
- First posted
- 2020-08-18
- Last updated
- 2023-11-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04516993. Inclusion in this directory is not an endorsement.